Ketogenic Therapy for Lysosomal Storage Disease Autophagy Support
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapy (ERT) for lysosomal storage diseases (LSDs) is limited by enzyme denaturation in the low pH environment of lysosomes, leading to low bioavailability and differential tissue responsiveness, and impaired autophagy contributes to substrate accumulation and cellular dysfunction.
Innovation Solution
Administration of a ketogenic agent, optionally combined with metabolic enhancing agents, to improve muscle function, autophagic activity, and mitochondrial capacity in individuals with LSDs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is administered intravenously, then the defective lysosomal enzyme is replaced in the circulation, but the infused enzyme denatures in the low pH environment of lysosomes leading to low bioavailability
Solution Approach 1:
The patent uses mannose-6-phosphate receptors as intermediaries to facilitate enzyme uptake. The recombinant GAA protein is engineered with mannose-6-phosphate tags that bind to these receptors on the cell surface, enabling targeted delivery and internalization through endocytosis, thereby protecting the enzyme from denaturation in the low pH lysosomal environment
Solution Approach 2:
The patent modifies the physical-chemical parameters of the enzyme by engineering recombinant GAA protein with specific mannose-6-phosphate modifications. This parameter change enables the enzyme to be recognized and internalized by cells through receptor-mediated endocytosis, improving its delivery efficiency and reducing denaturation losses
2Reliability
If enzyme replacement therapy is used, then enzymatic deficiency is addressed, but there is vast difference between different tissues with respect to their ability to respond to ERT
Solution Approach 1:
The patent applies local quality by engineering the enzyme with tissue-specific targeting capabilities through mannose-6-phosphate receptor binding. This allows differential delivery to various tissues based on their receptor expression levels, with skeletal muscle (especially type II fibers) and cardiac muscle receiving appropriate doses according to their specific needs and responsiveness
3Quantity of substance
If autophagy is impaired in lysosomal storage diseases, then substrate accumulates in lysosomes, but cellular function deteriorates due to accumulation of dysfunctional proteins
Solution Approach 1:
The patent employs preliminary action by administering recombinant GAA protein before significant cellular dysfunction occurs. The engineered enzyme with mannose-6-phosphate tags is delivered proactively to prevent substrate accumulation and maintain cellular function, rather than waiting for severe impairment to occur
Data Source
AI summary
A method for treating lysosomal storage disease in an individual is provided, comprising administering to the individual a ketogenic agent, a composition comprising a mixture of metabolic enhancing agents, or administering both the ketogenic agent and the metabolic enhancing composition. The treatment is effective to improve muscle function, autophagic activity and/or mitochondrial capacity in an individual having a lysosomal storage disease.